Before we get into the analysis of the Abbott call this morning let’s get the numbers out of the way; per the earnings release;
“In Diabetes Care, strong growth was led by FreeStyle Libre, which grew 36.8 percent on a reported basis and 39.9 percent on an organic basis versus the prior year. In June, Abbott announced U.S. FDA approval of FreeStyle Libre 2 as an integrated continuous glucose monitoring (iCGM) system for adults and children ages 4 and older with diabetes, achieving the highest level of accuracy and performance standards. The FreeStyle Libre 2 system . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.